A number of other equities research analysts have also recently weighed in on the company. SunTrust Banks decreased their price objective on AnaptysBio from $15.00 to $14.00 and set a “hold” rating for the company in a research note on Tuesday, March 3rd. Stifel Nicolaus restated a “hold” rating and set a $18.00 price objective on shares of AnaptysBio in a research note on Monday, March 2nd. ValuEngine upgraded AnaptysBio from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Finally, Zacks Investment Research cut AnaptysBio from a “buy” rating to a “hold” rating in a research note on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $49.00.
Shares of NASDAQ ANAB opened at $14.56 on Friday. The stock has a market capitalization of $368.35 million, a P/E ratio of -4.03 and a beta of 0.98. AnaptysBio has a 1-year low of $10.00 and a 1-year high of $83.10. The business has a fifty day moving average price of $15.42 and a 200 day moving average price of $22.01.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.45. The company had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.00 million. Analysts predict that AnaptysBio will post -2.51 EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in ANAB. Amundi Pioneer Asset Management Inc. purchased a new stake in AnaptysBio in the first quarter valued at about $110,000. Russell Investments Group Ltd. raised its stake in AnaptysBio by 35.0% in the third quarter. Russell Investments Group Ltd. now owns 21,617 shares of the biotechnology company’s stock valued at $757,000 after buying an additional 5,609 shares during the last quarter. Tower Research Capital LLC TRC purchased a new stake in AnaptysBio in the third quarter valued at about $66,000. State Street Corp raised its stake in AnaptysBio by 13.9% in the third quarter. State Street Corp now owns 1,090,980 shares of the biotechnology company’s stock valued at $38,173,000 after buying an additional 133,481 shares during the last quarter. Finally, Voloridge Investment Management LLC purchased a new stake in AnaptysBio in the third quarter valued at about $1,178,000.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
See Also: What is a price target?
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.